大麻与情绪障碍
Cannabis and Mood Disorders.
作者信息
Lucatch Aliya M, Coles Alexandria S, Hill Kevin P, George Tony P
机构信息
Addictions Division, Centre for Addictions and Mental Health (CAMH), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA USA.
Division of Addiction Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA USA.
出版信息
Curr Addict Rep. 2018 Sep;5(3):336-345. doi: 10.1007/s40429-018-0214-y. Epub 2018 May 10.
PURPOSE OF REVIEW
The present review will provide an overview of the neurobiology, epidemiology, clinical impact, and treatment of cannabis use disorder (CUD) in mood disorders.
RECENT FINDINGS
Patients with mood disorders including major depressive disorder (MDD) and bipolar disorder (BD) have higher rates of cannabis use, and CUD compared to the general population. Reasons for this association are not clear, nor are the putative therapeutic effects of cannabis use, or its components delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in these illnesses. The evidence surrounding treatments for patients with this comorbidity is lacking, with more support for psychotherapeutic treatments compared with pharmacological treatments.
SUMMARY
Cannabis use may be associated mood disorders, but more research is needed to increase our understanding of the mechanisms for this association, and to develop more effective treatments for this comorbidity.
综述目的
本综述将概述大麻使用障碍（CUD）在情绪障碍中的神经生物学、流行病学、临床影响及治疗。
最新发现
与普通人群相比，患有包括重度抑郁症（MDD）和双相情感障碍（BD）在内的情绪障碍患者使用大麻及患大麻使用障碍的比例更高。这种关联的原因尚不清楚，大麻使用及其成分Δ-9-四氢大麻酚（THC）和大麻二酚（CBD）在这些疾病中的假定治疗效果也不清楚。针对这种共病患者的治疗证据不足，与药物治疗相比，心理治疗得到的支持更多。
总结
大麻使用可能与情绪障碍有关，但需要更多研究来增进我们对这种关联机制的理解，并开发针对这种共病的更有效治疗方法。
Zotero 插件